Witnessing the stock’s movement on the chart, on Wednesday, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had a quiet start as it plunged -2.18% to $941.39, before settling in for the price of $962.34 at the close. Taking a more long-term approach, REGN posted a 52-week range of $769.19-$1211.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 19.99%. Meanwhile, its Annual Earning per share during the time was 10.31%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 2.22%. This publicly-traded company’s shares outstanding now amounts to $107.60 million, simultaneously with a float of $106.30 million. The organization now has a market capitalization sitting at $103.76 billion.
Regeneron Pharmaceuticals, Inc. (REGN) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Regeneron Pharmaceuticals, Inc.’s current insider ownership accounts for 3.55%, in contrast to 86.60% institutional ownership. According to the most recent insider trade that took place on Oct 01 ’24, this organization’s Director sold 100 shares at the rate of 1048.78, making the entire transaction reach 104,878 in total value, affecting insider ownership by 17,582. Preceding that transaction, on Oct 01 ’24, Company’s EVP Commercial sold 1,000 for 1054.06, making the whole transaction’s value amount to 1,054,060. This particular insider is now the holder of 12,931 in total.
Regeneron Pharmaceuticals, Inc. (REGN) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 11.78 per share during the current fiscal year.
Regeneron Pharmaceuticals, Inc.’s EPS increase for this current 12-month fiscal period is 2.22% and is forecasted to reach 47.63 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 6.00% through the next 5 years, which can be compared against the 10.31% growth it accomplished over the previous five years trading on the market.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Trading Performance Indicators
Let’s observe the current performance indicators for Regeneron Pharmaceuticals, Inc. (REGN). It’s Quick Ratio in the last reported quarter now stands at 4.62. The Stock has managed to achieve an average true range (ATR) of 24.32. Alongside those numbers, its PE Ratio stands at $24.93, and its Beta score is 0.11. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.69. Similarly, its price to free cash flow for trailing twelve months is now 31.17.
In the same vein, REGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 37.76, a figure that is expected to reach 11.72 in the next quarter, and analysts are predicting that it will be 47.63 at the market close of one year from today.
